# NT-101 Topical Ophthalmic Solution in Patients With Wet AMD

> **NCT06704009** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NexThera Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Wet Age Related Macular Degeneration
- Wet AMD

## Interventions

- **DRUG:** NT-101 Low Dose
- **DRUG:** NT-101 High Dose

## Key facts

- **NCT ID:** NCT06704009
- **Lead sponsor:** NexThera Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2025-12-15
- **Final completion:** 2026-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06704009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06704009, "NT-101 Topical Ophthalmic Solution in Patients With Wet AMD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06704009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*